Browse All

Current Filters

CLEAR FILTER x

TITLE

Real-world Persistence of Ofatumumab vs Self-injectable or Oral Disease-modifying Therapies in Patients with Multiple Sclerosis

Author:Hersh, Carrie   Gorritz, Magdaliz   Chen, Chi-Chang   Tuly, Rifat   Gu, Yifan   Shao, Qiujun   Gadkari, Abhijit   Brown, Brandon   

Session Name:P5: Multiple Sclerosis: Clinical Assessments Including Digital Tools and Outcome Measures 1  

Topic:Multiple Sclerosis  

Program Number:P5.012  

Author Institution:Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA, Las Vegas, NV  IQVIA, Plymouth Meeting, PA, USA, Plymouth Meeting, PA  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  

Immunoglobulin Level Changes in Patients with Multiple Sclerosis Treated with Anti-CD20 Monoclonal Antibodies

Author:Vollmer, Brandi   Bourassa, Timber   Marsh, Erin   Dao, Vi   Gadkari, Abhijit   Brown, Brandon   Sillau, Stefan   Nair, Kavita   Alvarez, Enrique   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.011  

Author Institution:University of Colorado, Aurora, CO  Novartis, East Hanover, NJ  

Real-world Effectiveness, Tolerability, and Safety of Ofatumumab at 12-month Follow-up

Author:Hersh, Carrie   Amin, Moein   Harvey, Tucker   Moss, Brandon   Tai, Ming-Hui   Gadkari, Abhijit   Brown, Brandon   Conway, Devon   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.014  

Author Institution:Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH  Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH  Novartis Pharmaceuticals Corporation, East Hanover, NJ